Eight Advisory supported Sanofi in its acquisition of Inhibrx

Sanofi, an innovation-driven global healthcare company, provides life-changing therapeutic solutions for patients. The addition of the INBRX-101 asset for the treatment of alpha-1 antitrypsin deficiency, a disease that primarily affects the lungs and leads to progressive tissue degradation, underlines the Group’s strategy to develop distinctive products.

Inhibrx is a publicly traded clinical-stage biopharmaceutical company specialising in the development of a broad portfolio of new biologic drug candidates. The company utilises a variety of protein engineering methodologies to address the specific needs of complex targets and diseases, including its proprietary protein engineering platforms.

Under the terms of the merger agreement, Sanofi will acquire all outstanding shares of Inhibrx for $30.0 per share in cash, representing an equity value of approximately $1.7 billion (on a fully diluted basis).

“We are pleased to have supported Sanofi in the financial due diligence review of this listed target company,” says Katia Wagner, Partner at Eight Advisory.

Eight Advisory team members supporting on this transaction :

– Financial Due Diligence: Katia Wagner, Partner, Laurent Williot, Partner, Louis Legros, Director, and Guillaume Heral, Manager.